SCHEMBL3097794

SCHEMBL3097794

CC(C)N(C(=O)C(CC1CC1)C(=O)NS(=O)(=O)c1ccc(-c2ccccc2)cc1)c1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 2/20 0.41
MCL1 Q07820 2/20 0.41
ADAMTS4 O75173 4/20 0.41
MMP1 P03956 3/20 0.41
ADAM17 P78536 1/20 0.41
ADAMTS1 Q9UHI8 1/20 0.41
ADAMTS7 Q9UKP4 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.41
MMP2 P08253 3/20 0.40
MMP3 P08254 2/20 0.40
MMP13 P45452 2/20 0.40
MMP9 P14780 2/20 0.40
MMP7 P09237 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CTSL P07711 3/20 0.39
CTSS P25774 2/20 0.39
CTSK P43235 2/20 0.39
USP30 Q70CQ3 3/20 0.39
MMP8 P22894 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092116 0.91 TARS1 (0.48) BCL2L1MCL1ADAMTS4MMP1ADAM17
SCHEMBL3087959 0.89 EGFR (0.45) MEN1KMT2AUSP30
SCHEMBL3092840 0.89 EGFR (0.44) MMP1MMP2MMP3MMP13MEN1
SCHEMBL3092864 0.88 LARS1 (0.48) MEN1KMT2ALARS1
SCHEMBL3083883 0.88 EGFR (0.48) MMP2MMP13MMP9MEN1KMT2A
SCHEMBL3089589 0.87 USP30 (0.42) CTSLUSP30
SCHEMBL3096770 0.87 EGFR (0.39) MEN1KMT2AUSP30
SCHEMBL3092667 0.86 LARS1 (0.47) BCL2L1MCL1ADAMTS4MMP1MMP2
SCHEMBL3092907 0.85 USP30 (0.41) USP30
SCHEMBL3091920 0.84 CCR5 (0.39) BCL2L1MCL1ADAMTS7ADAMTS5CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 BCL2L1 3351/4885MCL1 4465/4885ADAMTS4 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.